In the US, older women rely on the Medicare program disproportionality and significantly more than men. Not only do women make up more than half of the Medicare beneficiaries, we comprise about 70 percent of the oldest (over 85 years old) beneficiaries and are more likely to have multiple chronic conditions.

In the past, researchers excluded women from many studies and applied information based only on male participants to the experience of both men and women. Researchers did not design research to specifically investigate the differences between males and females because many people did not believe such differences existed. We now know many differences do exist and play a major role in the biological and physiological experiences of women and men.

Oncofertility is an interdisciplinary field at the intersection of oncology and reproductive medicine that expands fertility options for young cancer survivors. Experts in this field identify which cancer treatments are likely to damage later reproductive ability for men, women, and children and develop new fertility preservation methods. In addition, these scientists are also identifying cancer treatments that may be “fertoprotective” and prevent damage to the reproductive organs during cancer treatment. Every year, experts in this field meet to discuss the recent advances in oncofertility scientific and medical treatment.

According to a new study, vitamin D supplements may not reduce heart risks in older women as previously suggested. At total of 305 healthy postmenopausal women aged 60-70 yr were recruited and received a daily capsule of 400 or 1000 IU vitamin D3 or placebo.  Investigators found that the supplements did not have much of an impact on cholesterol, blood pressure and blood sugar.

Source:  Wood et.al.  J of Cl Endo & Metabolism, Aug 3, 2012.